Fukuda K, Yuasa K, Uchizono A, Matsuyama H, Shimada K, Ohyama M
Department of Otolaryngology, Kagoshima (Japan) University School of Medicine.
Arch Otolaryngol Head Neck Surg. 1989 Apr;115(4):515-8. doi: 10.1001/archotol.1989.01860280113028.
Sulfamethoxazole-trimethoprim, an antimicrobial agent, was used to treat three cases of cytotoxic agent-resistant Wegener's granulomatosis; one case was refractory to a regimen consisting of azathioprine and prednisolone, and in another two cases the therapy was insufficient to control the disease. By the introduction of sulfamethoxazole-trimethoprim, which has an advantage of fewer side effects compared with the conventional agents, into the regimen, the disease condition was markedly improved in all cases within four months. Sulfamethoxazole-trimethoprim is thus considered as one of the most promising drugs to treat, especially, cytotoxic agent-resistant Wegener's granulomatosis. The possible underlying mechanism of the effect of sulfamethoxazole-trimethoprim is also described.
抗菌药物磺胺甲恶唑-甲氧苄啶用于治疗3例对细胞毒性药物耐药的韦格纳肉芽肿病;1例对硫唑嘌呤和泼尼松龙组成的治疗方案无效,另外2例的治疗不足以控制病情。通过在治疗方案中引入磺胺甲恶唑-甲氧苄啶(与传统药物相比具有副作用较少的优势),所有病例的病情在4个月内均有明显改善。因此,磺胺甲恶唑-甲氧苄啶被认为是治疗尤其是对细胞毒性药物耐药的韦格纳肉芽肿病最有前景的药物之一。文中还描述了磺胺甲恶唑-甲氧苄啶作用的可能潜在机制。